Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas

Ana Fernandez-Teijeiro, Rebecca A. Betensky, Lisa M. Sturla, John Y.H. Kim, Pablo Tamayo, Scott L. Pomeroy

Research output: Contribution to journalArticlepeer-review


Purpose: Stratification of risk in patients with medulloblastoma remains a challenge. As clinical parameters have been proven insufficient for accurately defining disease risk, molecular markers have become the focus of interest. Outcome predictions on the basis of microarray gene expression profiles have been the most accurate to date. We ask in a multivariate model whether clinical parameters enhance survival predictions of gene expression profiles. Patients and Methods: In a cohort of 55 young patients (whose medulloblastoma samples have been analyzed previously for gene expression profile), associations between clinical and gene expression variables and survival were assessed using Cox proportional hazards models. Available clinical variables included age, stage (ie, the presence of disseminated disease at diagnosis), sex, histologic subtype, treatment, and status. Results: Univariate analysis demonstrated expression profiles to be the only significant clinical prognostic factor (P = .03). In multivariate analysis, gene expression profiles predicted outcome independent of other criteria. Clinical criteria did not significantly contribute additional information for outcome predictions, although an exploratory analysis noted a trend for decreased survival of patients with metastases at diagnosis but favorable gene expression profile. Conclusion: Gene expression profiling predicts medulloblastoma outcome independent of clinical variables. These results need to be validated in a larger prospective study.

Original languageEnglish (US)
Pages (from-to)994-998
Number of pages5
JournalJournal of Clinical Oncology
Issue number6
StatePublished - 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas'. Together they form a unique fingerprint.

Cite this